THOMAS SCIASCIA - 18 Feb 2025 Form 4 Insider Report for Trevi Therapeutics, Inc. (TRVI)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TRVI	Stock Option (right to buy)	Award	$0	+116,000		$0.000000	116,000	18 Feb 2025	Common Stock	116,000	$4.22	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	This option was granted on February 18, 2025. The 116,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 18, 2026 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 18, 2029.